Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Leflunomide"" wg kryterium: Temat

  Lista filtrów
Wyrównaj
Wyświetlanie 1-25 z 3495
Tytuł:
Leflunomide Treatment Does Not Protect Neural Cells following Oxygen-Glucose Deprivation (OGD) In Vitro.
Autorzy:
Curel CJM; Department of Comparative Biomedical Sciences, Royal Veterinary College, London NW1 0TU, UK.
Nobeli I; School of Natural Sciences, Institute of Structural and Molecular Biology, Birkbeck, University of London, London WC1E 7HX, UK.
Thornton C; Department of Comparative Biomedical Sciences, Royal Veterinary College, London NW1 0TU, UK.
Pokaż więcej
Źródło:
Cells [Cells] 2024 Apr 04; Vol. 13 (7). Date of Electronic Publication: 2024 Apr 04.
Typ publikacji:
Journal Article
MeSH Terms:
Oxygen*/metabolism
Mitochondrial Diseases*
Infant, Newborn ; Humans ; Glucose/metabolism ; Leflunomide/pharmacology ; Cells, Cultured
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Retrospective evaluation of prognosis and survival with various immunosuppressants in 82 dogs diagnosed with meningoencephalitis of unknown etiology (2010-2021).
Autorzy:
Kim SH; Laboratory of Veterinary Internal Medicine, Department of Veterinary Clinical Science, College of Veterinary Medicine, Seoul National University, Seoul, 00826, Republic of Korea.
Oh YI; Department of Veterinary Internal Medicine, College of Veterinary Medicine, Kyungpook National University, Daegu, 41566, Republic of Korea.
Park SM; Laboratory of Veterinary Internal Medicine, Department of Veterinary Clinical Science, College of Veterinary Medicine, Seoul National University, Seoul, 00826, Republic of Korea.
An JH; Department of Veterinary Emergency and Critical Care Medicine and Institute of Veterinary Science, College of Veterinary Medicine, Kangwon National University, Chuncheon-si, 24341, Republic of Korea.
Kim TH; Laboratory of Veterinary Internal Medicine, Department of Veterinary Clinical Science, College of Veterinary Medicine, Seoul National University, Seoul, 00826, Republic of Korea.
Kim SS; VIP Animal Medical Center KR, Seoul, 02830, Republic of Korea.
Ah JG; VIP Animal Medical Center KR, Seoul, 02830, Republic of Korea.
Seo KW; Laboratory of Veterinary Internal Medicine, Department of Veterinary Clinical Science, College of Veterinary Medicine, Seoul National University, Seoul, 00826, Republic of Korea.
Youn HY; Laboratory of Veterinary Internal Medicine, Department of Veterinary Clinical Science, College of Veterinary Medicine, Seoul National University, Seoul, 00826, Republic of Korea. .
Pokaż więcej
Źródło:
BMC veterinary research [BMC Vet Res] 2023 Dec 12; Vol. 19 (1), pp. 269. Date of Electronic Publication: 2023 Dec 12.
Typ publikacji:
Journal Article
MeSH Terms:
Meningoencephalitis*/drug therapy
Meningoencephalitis*/veterinary
Encephalomyelitis*/veterinary
Dog Diseases*/diagnosis
Humans ; Dogs ; Animals ; Immunosuppressive Agents/adverse effects ; Retrospective Studies ; Mycophenolic Acid/adverse effects ; Leflunomide/therapeutic use ; Prognosis ; Cytarabine/adverse effects
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Therapeutic response to leflunomide in combo therapy and monotherapy is associated to serum teriflunomide (A77 1726) levels.
Autorzy:
Fajardo-Robledo NS; Laboratorio de Investigación y Desarrollo Farmacéutico, Centro Universitario de Ciencias Exactas e Ingenierías, Universidad de Guadalajara, 44430, Guadalajara, Jalisco, Mexico.
Jacobo-Cuevas H; Programa de Doctorado en Farmacología, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, 44340, Guadalajara, Jalisco, Mexico.
Perez-Guerrero EE; Centro Universitario de Ciencias de la Salud, Instituto de Investigación en Ciencias Biomédicas, Universidad de Guadalajara, 44340, Guadalajara, Jalisco, Mexico.
Corona-Sanchez EG; Centro Universitario de Ciencias de la Salud, Instituto de Investigación en Reumatologia y del Sistema Musculo-Esqueletico, Universidad de Guadalajara, 44340, Guadalajara, Jalisco, Mexico.; Departamento de Fisiología, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, 44340, Guadalajara, Jalisco, Mexico.
Saldaña-Cruz AM; Departamento de Fisiología, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, 44340, Guadalajara, Jalisco, Mexico.
Romero-Tejeda EM; Departamento de Farmacobiologia, Centro Universitario de Ciencias Exactas e Ingenierías, Universidad de Guadalajara, 44430, Guadalajara, Jalisco, Mexico.
Rodriguez-Jimenez NA; Departamento de Fisiología, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, 44340, Guadalajara, Jalisco, Mexico.
Totsuka-Sutto SE; Departamento de Fisiología, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, 44340, Guadalajara, Jalisco, Mexico.
Lopez-Roa RI; Laboratorio de Investigación y Desarrollo Farmacéutico, Centro Universitario de Ciencias Exactas e Ingenierías, Universidad de Guadalajara, 44430, Guadalajara, Jalisco, Mexico.
Ponce-Guarneros JM; Departamento de Fisiología, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, 44340, Guadalajara, Jalisco, Mexico.; Instituto Mexicano del Seguro Social, UMF 97, 46474, Magdalena, Jalisco, Mexico.
Alcaraz-Lopez MF; Instituto Mexicano del Seguro Social, HGR 46, 44340, Guadalajara, Jalisco, Mexico.
Cerpa-Cruz S; División de Reumatología, Hospital Civil de Guadalajara 'Fray Antonio Alcalde', Guadalajara, Jalisco, México.
Muñoz-Valle JF; Centro Universitario de Ciencias de la Salud, Instituto de Investigación en Ciencias Biomédicas, Universidad de Guadalajara, 44340, Guadalajara, Jalisco, Mexico.
Cardona-Muñoz EG; Departamento de Fisiología, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, 44340, Guadalajara, Jalisco, Mexico.
Gonzalez-Lopez L; Programa de Doctorado en Farmacología, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, 44340, Guadalajara, Jalisco, Mexico. .; Departamento de Fisiología, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, 44340, Guadalajara, Jalisco, Mexico. .; Programa de Doctorado en Salud Publica, Departamento de Salud Publica, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico. .
Gamez-Nava JI; Programa de Doctorado en Farmacología, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, 44340, Guadalajara, Jalisco, Mexico. .; Departamento de Fisiología, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, 44340, Guadalajara, Jalisco, Mexico. .; Programa de Doctorado en Salud Publica, Departamento de Salud Publica, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico. .
Pokaż więcej
Corporate Authors:
Research Group for Factors Related to Therapeutic Outcomes in Autoimmune Diseases
Źródło:
Scientific reports [Sci Rep] 2022 Feb 03; Vol. 12 (1), pp. 1877. Date of Electronic Publication: 2022 Feb 03.
Typ publikacji:
Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Antirheumatic Agents/*therapeutic use
Arthritis, Rheumatoid/*drug therapy
Crotonates/*therapeutic use
Hydroxybutyrates/*therapeutic use
Leflunomide/*therapeutic use
Nitriles/*therapeutic use
Toluidines/*therapeutic use
Adult ; Aged ; Antirheumatic Agents/adverse effects ; Antirheumatic Agents/blood ; Arthritis, Rheumatoid/blood ; Arthritis, Rheumatoid/diagnosis ; Cross-Sectional Studies ; Crotonates/adverse effects ; Crotonates/blood ; Drug Monitoring ; Drug Therapy, Combination ; Female ; Humans ; Hydroxybutyrates/adverse effects ; Hydroxybutyrates/blood ; Leflunomide/adverse effects ; Leflunomide/blood ; Male ; Middle Aged ; Nitriles/adverse effects ; Nitriles/blood ; Predictive Value of Tests ; Remission Induction ; Severity of Illness Index ; Time Factors ; Toluidines/adverse effects ; Toluidines/blood ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Comparative analysis of multiorgan toxicity induced by long term use of disease modifying anti-rheumatic drugs.
Autorzy:
Mumtaz T; Faculty of Science and Technology, Department of Zoology, Government College Women University, Faisalabad, Punjab, Pakistan.
Tahir A; Faculty of Science and Technology, Department of Zoology, Government College Women University, Faisalabad, Punjab, Pakistan.
Tariq MA; Faculty of Science and Technology, Department of Zoology, Government College Women University, Faisalabad, Punjab, Pakistan.
Iqbal MA; Institute of Zoology, University of the Punjab, Lahore, Punjab, Pakistan.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2023 Aug 25; Vol. 18 (8), pp. e0290668. Date of Electronic Publication: 2023 Aug 25 (Print Publication: 2023).
Typ publikacji:
Case Reports; Journal Article
MeSH Terms:
Antirheumatic Agents*/adverse effects
Arthritis, Rheumatoid*/drug therapy
Renal Insufficiency*
Humans ; Methotrexate/adverse effects ; Leflunomide/adverse effects ; Uric Acid ; Creatinine ; Urea
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Management of ganciclovir resistance cytomegalovirus infection with CMV hyperimmune globulin and leflunomide in seven cardiothoracic transplant recipients and literature review.
Autorzy:
Santhanakrishnan K; Transplant Department, Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester, UK.
Yonan N; Transplant Department, Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester, UK.
Iyer K; Transplant Department, Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester, UK.
Callan P; Transplant Department, Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester, UK.
Al-Aloul M; Transplant Department, Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester, UK.
Venkateswaran R; Transplant Department, Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester, UK.
Pokaż więcej
Źródło:
Transplant infectious disease : an official journal of the Transplantation Society [Transpl Infect Dis] 2022 Feb; Vol. 24 (1), pp. e13733. Date of Electronic Publication: 2021 Oct 05.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Cytomegalovirus Infections*/drug therapy
Drug Resistance, Viral*
Globulins*/therapeutic use
Leflunomide*/therapeutic use
Antiviral Agents/therapeutic use ; Cytomegalovirus ; Ganciclovir/therapeutic use ; Humans ; Transplant Recipients
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Evaluation of Leflunomide Treatment in Patients with Juvenile Idiopathic Arthritis: A Single Center Experience.
Autorzy:
AYDIN, Elif ARSLANOĞLU
ÖZDEL, Semanur
BAĞRUL, İlknur
KOCAMAZ, Nesibe Gökce
BAĞLAN, Esra
TUNCEZ, Şerife
BÜLBÜL, Mehmet
Pokaż więcej
Alternatywny tytuł:
Jüvenil İdiopatik Artritli Hastalarda Leflunomid Tedavisinin Değerlendirilmesi: Tek Merkez Deneyimi.
Źródło:
Journal of Pediatric Disease / Türkiye Çocuk Hastalıkları Dergisi. may2023, Vol. 17 Issue 3, p214-218. 5p.
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
The Mitochondria-Independent Cytotoxic Effect of Leflunomide on RPMI-8226 Multiple Myeloma Cell Line.
Autorzy:
Adamczuk G; Independent Medical Biology Unit, Faculty of Pharmacy, Medical University of Lublin, 20-093 Lublin, Poland.
Humeniuk E; Independent Medical Biology Unit, Faculty of Pharmacy, Medical University of Lublin, 20-093 Lublin, Poland.
Iwan M; Department of Toxicology, Faculty of Pharmacy, Medical University of Lublin, 20-093 Lublin, Poland.
Natorska-Chomicka D; Department of Toxicology, Faculty of Pharmacy, Medical University of Lublin, 20-093 Lublin, Poland.
Adamczuk K; Department of Biochemistry and Molecular Biology, Faculty of Medicine, Medical University of Lublin, 20-093 Lublin, Poland.
Korga-Plewko A; Independent Medical Biology Unit, Faculty of Pharmacy, Medical University of Lublin, 20-093 Lublin, Poland.
Pokaż więcej
Źródło:
Molecules (Basel, Switzerland) [Molecules] 2021 Sep 17; Vol. 26 (18). Date of Electronic Publication: 2021 Sep 17.
Typ publikacji:
Journal Article
MeSH Terms:
Leflunomide*
Multiple Myeloma*
Antineoplastic Agents ; Apoptosis/drug effects ; Cell Cycle Checkpoints/drug effects ; Cell Line, Tumor ; Crotonates ; Enzyme Inhibitors/pharmacology ; Humans ; Hydroxybutyrates ; Membrane Potential, Mitochondrial/drug effects ; Nitriles ; Toluidines
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Subacute cutaneous lupus erythematosus as a rare complication of disease-modifying therapy administration in multiple sclerosis: case report.
Autorzy:
Xu K; Department of Neurology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.; National Health Commission Key Laboratory of Diagnosis and Treatment On Brain Functional Diseases, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Zhang M; Department of Neurology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Yang S; Department of Neurology, Huashan Hospital, Fudan University, Shanghai, China.
Yu G; Department of Neurology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Zheng P; Department of Neurology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.; National Health Commission Key Laboratory of Diagnosis and Treatment On Brain Functional Diseases, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Qin X; Department of Neurology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. .
Feng J; Department of Neurology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. .
Pokaż więcej
Źródło:
BMC neurology [BMC Neurol] 2023 Apr 26; Vol. 23 (1), pp. 168. Date of Electronic Publication: 2023 Apr 26.
Typ publikacji:
Review; Case Reports; Journal Article
MeSH Terms:
Multiple Sclerosis*/complications
Multiple Sclerosis*/drug therapy
Lupus Erythematosus, Cutaneous*/chemically induced
Lupus Erythematosus, Cutaneous*/diagnosis
Lupus Erythematosus, Cutaneous*/drug therapy
Humans ; Female ; Adult ; Hydroxychloroquine/adverse effects ; Leflunomide/adverse effects
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Successful treatment of nail involvement using leflunomide in a patient with synovitis, acne, pustulosis, hyperostosis and osteitis (SAPHO) syndrome.
Autorzy:
Li Z; Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Dongcheng-qu, China.
Liu S; Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Dongcheng-qu, China.
Liu Y; Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Dongcheng-qu, China.
Ma M; Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Dongcheng-qu, China.
Li L; Department of Dermatology, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Dongcheng-qu, China.
Li C; Department of Rheumatology, Fangshan Hospital Beijing University of Chinese Medicine, Beijing, China.
Pokaż więcej
Źródło:
The Australasian journal of dermatology [Australas J Dermatol] 2023 Feb; Vol. 64 (1), pp. 156-157. Date of Electronic Publication: 2022 Oct 30.
Typ publikacji:
Letter
MeSH Terms:
Osteitis*
Hyperostosis*
Synovitis*
Acne Vulgaris*
Humans ; Leflunomide/therapeutic use
Opinia redakcyjna
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Leflunomide: Traditional immunosuppressant with concurrent antiviral effects.
Autorzy:
Zheng K; Department of Rheumatology and Clinical Immunology, Chinese Academy of Medical Sciences & Peking Union Medical College; National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science & Technology; State Key Laboratory of Complex Severe and Rare Diseases, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Peking Union Medical College Hospital (PUMCH), Beijing, China.
Chen Y; Department of Rheumatology and Clinical Immunology, Chinese Academy of Medical Sciences & Peking Union Medical College; National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science & Technology; State Key Laboratory of Complex Severe and Rare Diseases, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Peking Union Medical College Hospital (PUMCH), Beijing, China.
Liu S; Department of Rheumatology and Clinical Immunology, Chinese Academy of Medical Sciences & Peking Union Medical College; National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science & Technology; State Key Laboratory of Complex Severe and Rare Diseases, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Peking Union Medical College Hospital (PUMCH), Beijing, China.
He C; Department of Rheumatology and Clinical Immunology, Chinese Academy of Medical Sciences & Peking Union Medical College; National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science & Technology; State Key Laboratory of Complex Severe and Rare Diseases, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Peking Union Medical College Hospital (PUMCH), Beijing, China.
Yang Y; Department of Rheumatology and Clinical Immunology, Chinese Academy of Medical Sciences & Peking Union Medical College; National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science & Technology; State Key Laboratory of Complex Severe and Rare Diseases, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Peking Union Medical College Hospital (PUMCH), Beijing, China.
Wu D; Department of Rheumatology and Clinical Immunology, Chinese Academy of Medical Sciences & Peking Union Medical College; National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science & Technology; State Key Laboratory of Complex Severe and Rare Diseases, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Peking Union Medical College Hospital (PUMCH), Beijing, China.
Wang L; Department of Rheumatology and Clinical Immunology, Chinese Academy of Medical Sciences & Peking Union Medical College; National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science & Technology; State Key Laboratory of Complex Severe and Rare Diseases, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Peking Union Medical College Hospital (PUMCH), Beijing, China.
Li M; Department of Rheumatology and Clinical Immunology, Chinese Academy of Medical Sciences & Peking Union Medical College; National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science & Technology; State Key Laboratory of Complex Severe and Rare Diseases, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Peking Union Medical College Hospital (PUMCH), Beijing, China.
Zeng X; Department of Rheumatology and Clinical Immunology, Chinese Academy of Medical Sciences & Peking Union Medical College; National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science & Technology; State Key Laboratory of Complex Severe and Rare Diseases, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Peking Union Medical College Hospital (PUMCH), Beijing, China.
Zhang F; Department of Rheumatology and Clinical Immunology, Chinese Academy of Medical Sciences & Peking Union Medical College; National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science & Technology; State Key Laboratory of Complex Severe and Rare Diseases, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Peking Union Medical College Hospital (PUMCH), Beijing, China.
Pokaż więcej
Źródło:
International journal of rheumatic diseases [Int J Rheum Dis] 2023 Feb; Vol. 26 (2), pp. 195-209. Date of Electronic Publication: 2022 Nov 13.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Immunosuppressive Agents*/adverse effects
Autoimmune Diseases*
Humans ; Leflunomide/therapeutic use ; Antiviral Agents/adverse effects ; Isoxazoles/adverse effects
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Efficacy of leflunomide combined with prednisone for the treatment of PLA2R-associated primary membranous nephropathy.
Autorzy:
Guo Y; Department of Nephrology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, People's Republic of China.
Wu X; Department of Nephrology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, People's Republic of China.
Liu L; Department of Nephrology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, People's Republic of China.
Zhang H; Department of Nephrology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, People's Republic of China.
Yang L; Department of Nephrology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, People's Republic of China.
Chen W; Department of Nephrology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, People's Republic of China.
Pokaż więcej
Źródło:
Renal failure [Ren Fail] 2020 Nov; Vol. 42 (1), pp. 122-130.
Typ publikacji:
Journal Article; Randomized Controlled Trial
MeSH Terms:
Glomerulonephritis, Membranous/*complications
Glomerulonephritis, Membranous/*drug therapy
Leflunomide/*therapeutic use
Nephrotic Syndrome/*complications
Prednisone/*therapeutic use
Adult ; Autoantibodies/blood ; Biomarkers/blood ; Cyclophosphamide/therapeutic use ; Drug Therapy, Combination ; Female ; Humans ; Immunosuppressive Agents/therapeutic use ; Leflunomide/adverse effects ; Male ; Middle Aged ; Prednisone/adverse effects ; Proteinuria/drug therapy ; Receptors, Phospholipase A2/immunology ; Remission Induction ; Serum Albumin
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Mitochondrial Quality Control and Metabolic Memory Phenomenon Associated with Continued Progression of Diabetic Retinopathy.
Autorzy:
Kowluru RA; Department of Ophthalmology, Visual and Anatomical Sciences, Wayne State University, Detroit, MI 48201, USA.
Alka K; Department of Ophthalmology, Visual and Anatomical Sciences, Wayne State University, Detroit, MI 48201, USA.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2023 Apr 29; Vol. 24 (9). Date of Electronic Publication: 2023 Apr 29.
Typ publikacji:
Journal Article
MeSH Terms:
Diabetic Retinopathy*/metabolism
Diabetes Mellitus*/metabolism
Rats ; Animals ; Humans ; Reactive Oxygen Species/metabolism ; Endothelial Cells/metabolism ; Leflunomide/pharmacology ; Rats, Wistar ; Mitochondria/metabolism ; DNA, Mitochondrial/genetics ; Glucose/metabolism ; Mitochondrial Dynamics
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Lipidic cubic-phase leflunomide nanoparticles (cubosomes) as a potential tool for breast cancer management.
Autorzy:
Zewail M; Pharmaceutics Department, Faculty of Pharmacy, Damanhour University, Damanhour, Egypt.
E Gaafar PM; Department of Pharmaceutics, Division of Pharmaceutical Sciences, College of Pharmacy, Arab Academy for Science, Technology and Maritime Transport, Alexandria, Egypt.
Ali MM; Department of Pharmaceutics, Division of Pharmaceutical Sciences, College of Pharmacy, Arab Academy for Science, Technology and Maritime Transport, Alexandria, Egypt.
Abbas H; Pharmaceutics Department, Faculty of Pharmacy, Damanhour University, Damanhour, Egypt.
Pokaż więcej
Źródło:
Drug delivery [Drug Deliv] 2022 Dec; Vol. 29 (1), pp. 1663-1674.
Typ publikacji:
Journal Article
MeSH Terms:
Breast Neoplasms*/drug therapy
Nanoparticles*/chemistry
Administration, Cutaneous ; Female ; Humans ; Leflunomide ; Particle Size
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Efficacy and safety of leflunomide combined with corticosteroids for the treatment of IgA nephropathy: a Meta-analysis of randomized controlled trials.
Autorzy:
Lv G; Key Laboratory of Microecology-immune Regulatory Network and Related Diseases, School of Basic Medicine, Jiamusi University, Jiamusi, Heilongjiang Province, China.
Ming C; Department of Urology, Jiamusi Central Hospital, Jiamusi, China.
Pokaż więcej
Źródło:
Renal failure [Ren Fail] 2022 Dec; Vol. 44 (1), pp. 1011-1025.
Typ publikacji:
Journal Article; Meta-Analysis
MeSH Terms:
Glomerulonephritis, IGA*/drug therapy
Adrenal Cortex Hormones/adverse effects ; Humans ; Leflunomide/adverse effects ; Proteinuria/drug therapy ; Randomized Controlled Trials as Topic
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Comparison of the efficacy and safety of methotrexate alone or in combination with leflunomide in the treatment of juvenile idiopathic arthritis: a double-blind, placebo-controlled, randomized trial.
Autorzy:
Rezaieyazdi, Zahra
Ravanshad, Sahar
Khodashahi, Mandana
Bokaeian, Maliheh
Majd, Hassan Mehrad
Salari, Masoumeh
Pokaż więcej
Źródło:
Rheumatology / Reumatologia. 2023, Vol. 61 Issue 1, p4-12. 9p.
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Effectiveness of Different Rituximab Doses Combined with Leflunomide in the Treatment or Retreatment of Rheumatoid Arthritis: Part 2 of a Randomized, Placebo-Controlled, Investigator-Initiated Clinical Trial (AMARA).
Autorzy:
Koehm, Michaela (AUTHOR)
Foldenauer, Ann C. (AUTHOR)
Rossmanith, Tanja (AUTHOR)
Alten, Rieke (AUTHOR)
Aringer, Martin (AUTHOR)
Backhaus, Marina (AUTHOR)
Burmester, Gerd R. (AUTHOR)
Feist, Eugen (AUTHOR)
Kellner, Herbert (AUTHOR)
Krueger, Klaus (AUTHOR)
Müller-Ladner, Ulf (AUTHOR)
Rubbert-Roth, Andrea (AUTHOR)
Tony, Hans-Peter (AUTHOR)
Wassenberg, Siegfried (AUTHOR)
Burkhardt, Harald (AUTHOR)
Behrens, Frank (AUTHOR)
Pokaż więcej
Źródło:
Journal of Clinical Medicine. Dec2022, Vol. 11 Issue 24, p7316. 13p.
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Encapsulation of Leflunomide (LFD) in a novel niosomal formulation facilitated its delivery to THP-1 monocytic cells and enhanced Aryl hydrocarbon receptor (AhR) nuclear translocation and activation.
Autorzy:
Hasani M; Department of Medical Biotechnology, School of Advanced Technologies in Medicine, Golestan University of Medical Sciences, Gorgan, Iran.
Sani NA; Department of Medical Biotechnology, School of Advanced Technologies in Medicine, Golestan University of Medical Sciences, Gorgan, Iran.
Khodabakhshi B; Infectious Diseases Research Center, Golestan University of Medical Sciences, Gorgan, Iran.
Arabi MS; Medical Cellular and Molecular Research Center, Golestan University of Medical Sciences, Gorgan, Iran.
Mohammadi S; Infectious Diseases Research Center, Golestan University of Medical Sciences, Gorgan, Iran.; Stem Cell Research Center, Golestan University of Medical Sciences, Po.Box: 4934174611, Gorgan, Iran.
Yazdani Y; Infectious Diseases Research Center, Golestan University of Medical Sciences, Gorgan, Iran. .; Stem Cell Research Center, Golestan University of Medical Sciences, Po.Box: 4934174611, Gorgan, Iran. .
Pokaż więcej
Źródło:
Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences [Daru] 2019 Dec; Vol. 27 (2), pp. 635-644. Date of Electronic Publication: 2019 Aug 20.
Typ publikacji:
Journal Article
MeSH Terms:
Basic Helix-Loop-Helix Transcription Factors/*metabolism
Leflunomide/*pharmacology
Monocytes/*metabolism
Receptors, Aryl Hydrocarbon/*metabolism
Capsules ; Cytochrome P-450 CYP1A1/genetics ; Drug Compounding ; Humans ; Interleukin-1beta/genetics ; Leflunomide/adverse effects ; Leflunomide/chemistry ; Liposomes ; Monocytes/cytology ; Monocytes/drug effects ; Protein Transport/drug effects ; Surface-Active Agents/chemistry ; THP-1 Cells
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Comparing methotrexate monotherapy with methotrexate plus leflunomide combination therapy in psoriatic arthritis: protocol of a randomized, placebo-controlled, double-blind clinical trial (COMPLETE-PsA).
Autorzy:
Mulder MLM; Department of Rheumatology, Sint Maartenskliniek, PO Box 9011, Nijmegen, 6500 GM, The Netherlands. .; Department of Rheumatic Diseases, Radboud University Medical Center, Nijmegen, The Netherlands. .
Vriezekolk JE; Department of Rheumatology, Sint Maartenskliniek, PO Box 9011, Nijmegen, 6500 GM, The Netherlands.
den Broeder N; Department of Rheumatology, Sint Maartenskliniek, PO Box 9011, Nijmegen, 6500 GM, The Netherlands.
Mahler EAM; Department of Rheumatology, Sint Maartenskliniek, PO Box 9011, Nijmegen, 6500 GM, The Netherlands.
Helliwell PS; Leeds Institute of Rheumatology and Musculoskeletal Medicine, University of Leeds, Leeds, UK.
van den Hoogen FHJ; Department of Rheumatology, Sint Maartenskliniek, PO Box 9011, Nijmegen, 6500 GM, The Netherlands.; Department of Rheumatic Diseases, Radboud University Medical Center, Nijmegen, The Netherlands.
den Broeder AA; Department of Rheumatology, Sint Maartenskliniek, PO Box 9011, Nijmegen, 6500 GM, The Netherlands.; Department of Rheumatic Diseases, Radboud University Medical Center, Nijmegen, The Netherlands.
Wenink MH; Department of Rheumatology, Sint Maartenskliniek, PO Box 9011, Nijmegen, 6500 GM, The Netherlands.
Pokaż więcej
Źródło:
Trials [Trials] 2020 Feb 10; Vol. 21 (1), pp. 155. Date of Electronic Publication: 2020 Feb 10.
Typ publikacji:
Clinical Trial Protocol; Journal Article
MeSH Terms:
Antirheumatic Agents/*administration & dosage
Arthritis, Psoriatic/*drug therapy
Immunosuppressive Agents/*administration & dosage
Leflunomide/*administration & dosage
Methotrexate/*administration & dosage
Adolescent ; Adult ; Aged ; Aged, 80 and over ; Antirheumatic Agents/adverse effects ; Double-Blind Method ; Drug Therapy, Combination ; Female ; Humans ; Immunosuppressive Agents/adverse effects ; Leflunomide/adverse effects ; Male ; Methotrexate/adverse effects ; Middle Aged ; Quality of Life ; Randomized Controlled Trials as Topic ; Treatment Outcome ; Young Adult
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Combination of leflunomide and benazepril reduces renal injury of diabetic nephropathy rats and inhibits high-glucose induced cell apoptosis through regulation of NF-κB, TGF-β and TRPC6.
Autorzy:
Li H; Department of Nephrology, Xixi Hospital of Hangzhou (Hangzhou XIXI Affiliated Hospital of Zhejiang Chinese Medical University) , Hangzhou , Zhejiang Province , People's Republic of China.
Wang Y; Department of Nephrology, Xixi Hospital of Hangzhou (Hangzhou XIXI Affiliated Hospital of Zhejiang Chinese Medical University) , Hangzhou , Zhejiang Province , People's Republic of China.
Zhou Z; Department of Nephrology, Xixi Hospital of Hangzhou (Hangzhou XIXI Affiliated Hospital of Zhejiang Chinese Medical University) , Hangzhou , Zhejiang Province , People's Republic of China.
Tian F; Department of Nephrology, Xixi Hospital of Hangzhou (Hangzhou XIXI Affiliated Hospital of Zhejiang Chinese Medical University) , Hangzhou , Zhejiang Province , People's Republic of China.
Yang H; Department of Nephrology, Xixi Hospital of Hangzhou (Hangzhou XIXI Affiliated Hospital of Zhejiang Chinese Medical University) , Hangzhou , Zhejiang Province , People's Republic of China.
Yan J; Department of Nephrology, Xixi Hospital of Hangzhou (Hangzhou XIXI Affiliated Hospital of Zhejiang Chinese Medical University) , Hangzhou , Zhejiang Province , People's Republic of China.
Pokaż więcej
Źródło:
Renal failure [Ren Fail] 2019 Nov; Vol. 41 (1), pp. 899-906.
Typ publikacji:
Journal Article
MeSH Terms:
Apoptosis/*drug effects
Benzazepines/*pharmacology
Diabetes Mellitus, Experimental/*complications
Diabetic Nephropathies/*drug therapy
Hyperglycemia/*complications
Leflunomide/*pharmacology
Animals ; Benzazepines/therapeutic use ; Blood Glucose/analysis ; Cell Line ; Diabetes Mellitus, Experimental/blood ; Diabetes Mellitus, Experimental/chemically induced ; Diabetic Nephropathies/etiology ; Diabetic Nephropathies/pathology ; Drug Synergism ; Drug Therapy, Combination ; Glomerular Filtration Rate/drug effects ; Humans ; Hyperglycemia/blood ; Hyperglycemia/chemically induced ; Leflunomide/therapeutic use ; Male ; Mesangial Cells/drug effects ; Mesangial Cells/pathology ; NF-kappa B/metabolism ; Rats ; Rats, Sprague-Dawley ; Signal Transduction/drug effects ; Streptozocin/toxicity ; TRPC Cation Channels/metabolism ; Transforming Growth Factor beta/metabolism
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Efficacy and safety of leflunomide in psoriatic arthritis treatment: A single-arm meta-analysis.
Autorzy:
Dai Q; Department of Rheumatology and Immunology, First Affiliated Hospital of Zhejiang, Chinese Medical University, Hangzhou, China.; The First Clinical Medical College of Zhejiang, Chinese Medical University, Hangzhou, China.
Xu L; Department of Rheumatology and Immunology, First Affiliated Hospital of Zhejiang, Chinese Medical University, Hangzhou, China.
Yu X; Department of Rheumatology and Immunology, First Affiliated Hospital of Zhejiang, Chinese Medical University, Hangzhou, China.
Pokaż więcej
Źródło:
International journal of rheumatic diseases [Int J Rheum Dis] 2019 Aug; Vol. 22 (8), pp. 1498-1505. Date of Electronic Publication: 2019 May 27.
Typ publikacji:
Journal Article; Meta-Analysis; Systematic Review
MeSH Terms:
Arthritis, Psoriatic/*drug therapy
Immunosuppressive Agents/*therapeutic use
Leflunomide/*therapeutic use
Adult ; Arthritis, Psoriatic/diagnosis ; Arthritis, Psoriatic/immunology ; Female ; Humans ; Immunosuppressive Agents/adverse effects ; Leflunomide/adverse effects ; Male ; Middle Aged ; Quality of Life ; Remission Induction ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Leflunomide versus methotrexate in treatment of giant cell arteritis: comparison of efficacy, safety, and drug survival.
Autorzy:
Tengesdal S; a Department of Rheumatology , Hospital of Southern Norway , Kristiansand , Norway.
Diamantopoulos AP; b Department of Rheumatology , Martina Hansen Hospital , Baerum , Norway.
Myklebust G; a Department of Rheumatology , Hospital of Southern Norway , Kristiansand , Norway.
Pokaż więcej
Źródło:
Scandinavian journal of rheumatology [Scand J Rheumatol] 2019 Jul; Vol. 48 (4), pp. 333-335. Date of Electronic Publication: 2019 Mar 05.
Typ publikacji:
Comparative Study; Letter; Observational Study
MeSH Terms:
Giant Cell Arteritis*/diagnosis
Giant Cell Arteritis*/drug therapy
Giant Cell Arteritis*/epidemiology
Leflunomide*/administration & dosage
Leflunomide*/adverse effects
Methotrexate*/administration & dosage
Methotrexate*/adverse effects
Aged ; Antirheumatic Agents/administration & dosage ; Antirheumatic Agents/adverse effects ; Dose-Response Relationship, Drug ; Drug Monitoring/methods ; Female ; Humans ; Male ; Norway/epidemiology ; Patient Acuity ; Prednisolone/administration & dosage ; Prednisolone/adverse effects ; Remission Induction/methods ; Retrospective Studies ; Treatment Outcome
Raport
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Efficacy of leflunomide in the treatment of palindromic rheumatism.
Autorzy:
Sadri M; Connective Tissue Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Esalatmanesh K; Internal Medicine Department, Medical Faculty, Kashan University of Medical Sciences, Kashan, Iran.
Khabbazi A; Connective Tissue Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Pokaż więcej
Źródło:
International journal of rheumatic diseases [Int J Rheum Dis] 2022 Aug; Vol. 25 (8), pp. 893-896. Date of Electronic Publication: 2022 Jun 06.
Typ publikacji:
Journal Article
MeSH Terms:
Antirheumatic Agents*/adverse effects
Arthritis, Rheumatoid*/diagnosis
Arthritis, Rheumatoid*/drug therapy
Drug Therapy, Combination ; Humans ; Leflunomide/adverse effects ; Methotrexate/adverse effects ; Prednisolone/therapeutic use ; Retrospective Studies ; Treatment Outcome
SCR Disease Name:
Palindromic rheumatism
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Development and Evaluation of Novel Leflunomide SPION Bioemulsomes for the Intra-Articular Treatment of Arthritis.
Autorzy:
Abbas, Haidy (AUTHOR)
Gad, Heba A. (AUTHOR)
El Sayed, Nesrine S (AUTHOR)
Rashed, Laila Ahmed (AUTHOR)
Khattab, Mohamed A. (AUTHOR)
Noor, Ahmad O. (AUTHOR)
Zewail, Mariam (AUTHOR)
Pokaż więcej
Źródło:
Pharmaceutics. Oct2022, Vol. 14 Issue 10, pN.PAG-N.PAG. 23p.
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Efficacy and safety of add-on tacrolimus versus leflunomide in rheumatoid arthritis patients with inadequate response to methotrexate.
Autorzy:
Shin K; Division of Rheumatology, Seoul Metropolitan Government-Seoul National University Boramae Medical Center, Seoul, Korea.
Baek HJ; Division of Rheumatology, Department of Internal Medicine, Gachon University Gil Medical Center, Incheon, Korea.
Kang YM; Division of Rheumatology, Department of Internal Medicine, Kyungpook National University Hospital, Daegu, Korea.
Cha HS; Division of Rheumatology, Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University, Seoul, Korea.
Kang SW; Division of Rheumatology, Department of Internal Medicine, Chungnam National University Hospital, Daejeon, Korea.
Park SH; Division of Rheumatology, Department of Internal Medicine, Catholic University of Korea, Seoul St Mary's Hospital, Seoul, Korea.
Jun JB; Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea.
Lee YJ; Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea.
Choi IA; Division of Rheumatology, Department of Internal Medicine, Chungbuk National University Hospital, Cheongju, Korea.
Song YW; Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.; Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, College of Medicine, Medical Research Institute, Seoul National University, Seoul, Korea.
Pokaż więcej
Źródło:
International journal of rheumatic diseases [Int J Rheum Dis] 2019 Jun; Vol. 22 (6), pp. 1115-1122. Date of Electronic Publication: 2019 Mar 12.
Typ publikacji:
Comparative Study; Equivalence Trial; Journal Article; Multicenter Study
MeSH Terms:
Arthritis, Rheumatoid/*drug therapy
Immunosuppressive Agents/*administration & dosage
Leflunomide/*administration & dosage
Methotrexate/*administration & dosage
Tacrolimus/*administration & dosage
Adult ; Aged ; Aged, 80 and over ; Arthritis, Rheumatoid/diagnosis ; Arthritis, Rheumatoid/immunology ; Double-Blind Method ; Drug Therapy, Combination ; Female ; Humans ; Immunosuppressive Agents/adverse effects ; Leflunomide/adverse effects ; Male ; Methotrexate/adverse effects ; Middle Aged ; Republic of Korea ; Severity of Illness Index ; Tacrolimus/adverse effects ; Time Factors ; Treatment Outcome ; Young Adult
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Wyświetlanie 1-25 z 3495

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies